Utility of serum procalcitonin values in patients with acute exacerbations of chronic obstructive pulmonary disease: a cautionary note
Authors Falsey A, Becker K, Swinburn A, Nylen E, Snider, Formica M, Hennessey, Criddle M, Peterson, Walsh E
Received 15 December 2011
Accepted for publication 12 January 2012
Published 23 February 2012 Volume 2012:7 Pages 127—135
Review by Single-blind
Peer reviewer comments 3
Ann R Falsey1,2, Kenneth L Becker3, Andrew J Swinburne2, Eric S Nylen3, Richard H Snider3, Maria A Formica2, Patricia A Hennessey2, Mary M Criddle2, Derick R Peterson4, Edward E Walsh1,2
1Department of Medicine, University of Rochester, 2Rochester General Hospital, Rochester, NY, 3Veterans Affairs Medical Center and George Washington University, Washington DC, 4Biostatistics and Computational Biology, University of Rochester, Rochester, NY, USA
Background: Serum procalcitonin levels have been used as a biomarker of invasive bacterial infection and recently have been advocated to guide antibiotic therapy in patients with chronic obstructive pulmonary disease (COPD). However, rigorous studies correlating procalcitonin levels with microbiologic data are lacking. Acute exacerbations of COPD (AECOPD) have been linked to viral and bacterial infection as well as noninfectious causes. Therefore, we evaluated procalcitonin as a predictor of viral versus bacterial infection in patients hospitalized with AECOPD with and without evidence of pneumonia.
Methods: Adults hospitalized during the winter with symptoms consistent with AECOPD underwent extensive testing for viral, bacterial, and atypical pathogens. Serum procalcitonin levels were measured on day 1 (admission), day 2, and at one month. Clinical and laboratory features of subjects with viral and bacterial diagnoses were compared.
Results: In total, 224 subjects with COPD were admitted for 240 respiratory illnesses. Of these, 56 had pneumonia and 184 had AECOPD alone. A microbiologic diagnosis was made in 76 (56%) of 134 illnesses with reliable bacteriology (26 viral infection, 29 bacterial infection, and 21 mixed viral bacterial infection). Mean procalcitonin levels were significantly higher in patients with pneumonia compared with AECOPD. However, discrimination between viral and bacterial infection using a 0.25 ng/mL threshold for bacterial infection in patients with AECOPD was poor.
Conclusion: Procalcitonin is useful in COPD patients for alerting clinicians to invasive bacterial infections such as pneumonia but it does not distinguish bacterial from viral and noninfectious causes of AECOPD.
Keywords: virus, bacterial infection, procalcitonin, chronic obstructive pulmonary disease, bronchitis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]